進行性固形腫瘍患者におけるSyB C-0501（経口ベンダムスチン）の効果

基本情報

NCT ID

NCT03604679

ステータス

完了

試験のフェーズ

第1相

試験タイプ

介入

目標被験者数

18

治験依頼者名

SymBio Pharmaceuticals

概要

This study is an open-label, multicenter, phase 1 study of SyB C-0501 by continuous daily oral administration in patients with advanced solid tumors, who have previously received anticancer therapy and consists of two parts. Part 1 is a dose escalation study to evaluate tolerability of SyB C-0501 in the patients, and to find the maximum tolerated dose (MTD), recommended dose (RD) and optimum dosing schedule. Part 2 is being done to evaluate safety and anti-tumor activity of SyB C-0501 preliminarily at RD, and to assess its target cancer exploratory.

対象疾患

介入

依頼者（Sponsor）